Diagnostic Accuracy of 1-3 Beta-D-Glucan for Pneumocystis jirovecii Pneumonia

Key Limitations and Cross-Reactivity

The Infectious Diseases Society of America states that 1-3 beta-D-glucan (BDG) is not specific for any single fungal pathogen, and will be positive in other invasive fungal infections, including candidiasis, aspergillosis, and fusariosis, with a specificity ranging from 84-94% in immunocompromised patients 1, 2
BDG test will be positive in candidiasis, aspergillosis, fusariosis, and pneumocystis jirovecii pneumonia, indicating fungal invasion but cannot distinguish PCP from other invasive mycoses 1, 2

Multiple non-fungal conditions cause false-positive BDG results, including amoxicillin-clavulanate, piperacillin-tazobactam, cephalosporins, carbapenems, and hemodialysis, further reducing specificity 1, 2, 3
Glucan-contaminated blood collection tubes or surgical gauze, mucositis or gastrointestinal mucosal disruption, and plasmalyte in BAL fluids can also cause false-positive results 1, 2, 3

Requiring consecutive positive results rather than a single test can improve specificity, as recommended by the Infectious Diseases Society of America 3
BDG does not detect mucormycosis or most Cryptococcus species, and negative BDG is meaningless if these are suspected 3
Checking for confounding medications and conditions, such as amoxicillin-clavulanate and hemodialysis, is crucial before interpreting positive results 1, 2, 3
BDG performs poorly in lung transplant recipients, with a specificity as low as 9% and a positive predictive value of only 14% 3